<?xml version='1.0' encoding='utf-8'?>
<document id="25114132"><sentence text="Pharmacokinetics of para-aminosalicylic acid in HIV-uninfected and HIV-coinfected tuberculosis patients receiving antiretroviral therapy, managed for multidrug-resistant and extensively drug-resistant tuberculosis."><entity charOffset="20-44" id="DDI-PubMed.25114132.s1.e0" text="para-aminosalicylic acid" /></sentence><sentence text="The emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Mycobacterium tuberculosis prompted the reintroduction of para-aminosalicylic acid (PAS) to protect companion anti-tuberculosis drugs from additional acquired resistance"><entity charOffset="138-162" id="DDI-PubMed.25114132.s2.e0" text="para-aminosalicylic acid" /><entity charOffset="164-167" id="DDI-PubMed.25114132.s2.e1" text="PAS" /><pair ddi="false" e1="DDI-PubMed.25114132.s2.e0" e2="DDI-PubMed.25114132.s2.e0" /><pair ddi="false" e1="DDI-PubMed.25114132.s2.e0" e2="DDI-PubMed.25114132.s2.e1" /></sentence><sentence text=" In sub-Saharan Africa, MDR/XDR tuberculosis with HIV coinfection is common, and concurrent treatment of HIV infection and MDR/XDR tuberculosis is required" /><sentence text=" Out of necessity, patients receive multiple drugs, and PAS therapy is frequent; however, neither potential drug interactions nor the effects of HIV infection are known"><entity charOffset="56-58" id="DDI-PubMed.25114132.s4.e0" text="PAS" /></sentence><sentence text=" Potential drug-drug interaction with PAS and the effect of HIV infection was examined in 73 pulmonary tuberculosis patients; 22 (30"><entity charOffset="38-40" id="DDI-PubMed.25114132.s5.e0" text="PAS" /></sentence><sentence text="1%) were HIV coinfected" /><sentence text=" Forty-one pulmonary MDR or XDR tuberculosis patients received 4 g PAS twice daily, and in a second crossover study, another 32 patients were randomized, receiving 4 g PAS twice daily or 8 g PAS once daily"><entity charOffset="67-69" id="DDI-PubMed.25114132.s7.e0" text="PAS" /><entity charOffset="168-170" id="DDI-PubMed.25114132.s7.e1" text="PAS" /><entity charOffset="191-193" id="DDI-PubMed.25114132.s7.e2" text="PAS" /><pair ddi="false" e1="DDI-PubMed.25114132.s7.e0" e2="DDI-PubMed.25114132.s7.e0" /><pair ddi="false" e1="DDI-PubMed.25114132.s7.e0" e2="DDI-PubMed.25114132.s7.e1" /><pair ddi="false" e1="DDI-PubMed.25114132.s7.e0" e2="DDI-PubMed.25114132.s7.e2" /><pair ddi="false" e1="DDI-PubMed.25114132.s7.e1" e2="DDI-PubMed.25114132.s7.e1" /><pair ddi="false" e1="DDI-PubMed.25114132.s7.e1" e2="DDI-PubMed.25114132.s7.e2" /></sentence><sentence text=" A PAS population pharmacokinetic model in two dosing regimens was developed; potential covariates affecting its pharmacokinetics were examined, and Monte Carlo simulations were conducted evaluating the pharmacokinetic-pharmacodynamic index"><entity charOffset="3-5" id="DDI-PubMed.25114132.s8.e0" text="PAS" /></sentence><sentence text=" The probability of target attainment (PTA) to maintain PAS levels above MIC during the dosing interval was estimated by simulation of once-, twice-, and thrice-daily dosing regimens not exceeding 12 g daily"><entity charOffset="56-58" id="DDI-PubMed.25114132.s9.e0" text="PAS" /></sentence><sentence text=" Concurrent efavirenz (EFV) medication resulted in a 52% increase in PAS clearance and a corresponding &gt;30% reduction in mean PAS area under the concentration curve in 19 of 22 HIV-M"><entity charOffset="12-21" id="DDI-PubMed.25114132.s10.e0" text="efavirenz" /><entity charOffset="69-77" id="DDI-PubMed.25114132.s10.e1" text="PAS" /><entity charOffset="126-134" id="DDI-PubMed.25114132.s10.e2" text="PAS" /><pair ddi="false" e1="DDI-PubMed.25114132.s10.e0" e2="DDI-PubMed.25114132.s10.e0" /><pair ddi="false" e1="DDI-PubMed.25114132.s10.e0" e2="DDI-PubMed.25114132.s10.e1" /><pair ddi="false" e1="DDI-PubMed.25114132.s10.e0" e2="DDI-PubMed.25114132.s10.e2" /><pair ddi="false" e1="DDI-PubMed.25114132.s10.e1" e2="DDI-PubMed.25114132.s10.e1" /><pair ddi="false" e1="DDI-PubMed.25114132.s10.e1" e2="DDI-PubMed.25114132.s10.e2" /></sentence><sentence text=" tuberculosis-coinfected patients" /><sentence text=" Current practice recommends maintenance of PAS concentrations at ≥1 μg/ml (the MIC of M"><entity charOffset="44-46" id="DDI-PubMed.25114132.s12.e0" text="PAS" /></sentence><sentence text=" tuberculosis), but the model predicts that at only a minimum dose of 4 g twice daily can this PTA be achieved in at least 90% of the population, whether or not EFV is concomitantly administered" /><sentence text=" Once-daily dosing of 12 g PAS will not provide PAS concentrations exceeding the MIC over the entire dosing interval if coadministered with EFV, while 4 g twice daily ensures concentrations exceeding MIC over the entire dosing interval, even in HIV-infected patients who received EFV"><entity charOffset="27-29" id="DDI-PubMed.25114132.s14.e0" text="PAS" /><entity charOffset="48-50" id="DDI-PubMed.25114132.s14.e1" text="PAS" /><pair ddi="false" e1="DDI-PubMed.25114132.s14.e0" e2="DDI-PubMed.25114132.s14.e0" /><pair ddi="false" e1="DDI-PubMed.25114132.s14.e0" e2="DDI-PubMed.25114132.s14.e1" /></sentence><sentence text=" " /></document>